The Red Cross’s inclusive assessment will determine blood donation eligibility; Wegovy reduces the risk of cardiovascular events; the first postpartum depression pill sparks pricing questions.
Red Cross Implements More Inclusive Blood Donation Policy
The American Red Cross is implementing a more inclusive risk-based assessment to determine blood donation eligibility, eliminating the previous ban that prevented most gay men from donating blood, according to CNN. This shift comes after decades of stigmatizing guidance from the FDA. The new policy focuses on behavior rather than sexual orientation—deferring potential donors if they have had a new sexual partner, more than one partner, or anal sex in the previous 3 months—allowing more individuals to contribute to the blood supply. Those currently taking pre- and postexposure prophylaxis also remain deferred, with the FDA highlighting the potential for false-negative results on an HIV test. Although this change is seen as a significant step toward inclusivity, some critics argue that the policy still excludes certain groups, including
Obesity Drug Wegovy Shows Cardiovascular Benefit in Major Study
Wegovy from Novo Nordisk has demonstrated an additional medical benefit beyond weight loss in a significant late-stage study, according to Reuters. The weekly injection, aimed at overweight or obese individuals with a history of heart disease, showed a 20% reduction in the risk of major cardiovascular events—including heart attack, stroke, or death from heart disease—compared with placebo. This outcome exceeded the anticipated 15% to 17% reduction. The trial involved 17,500 patients and is expected to influence insurers and health authorities to consider covering the drug’s cost for a broader patient population. Novo Nordisk plans to seek regulatory approvals for expanding Wegovy's label indication in the United States and Europe based on the study results.
Questions Linger on Pricing of Postpartum Depression Pill
The recent FDA approval of the first pill to treat postpartum depression, zuranolone (Zurzuvae), has raised concerns about its pricing, which could subsequently have an impact on its accessibility and prescription rates, according to Axios. The drug’s manufacturer, Sage Therapeutics, has yet to decide on the pricing, and this decision might be influenced by the drug's failure to gain approval for treating major depressive disorder. Analysts have revised down sales projections for zuranolone, and experts have noted that the drug’s boxed warnings and potential limitations could affect its uptake.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More